S8APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hosseini, Iraj ^a   Mac Gabhann, Feilim ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE;

APOPTOSIS; ARTICLE; CD34 SELECTION; CD4+ T LYMPHOCYTE; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MATHEMATICAL MODEL; NONHUMAN; SIMULATION; STEM CELL TRANSPLANTATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; ALGORITHM; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; COMPUTER SIMULATION; GENE EXPRESSION; GENETICS; HEMATOPOIETIC STEM CELL; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; VIROLOGY;

ALGORITHMS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; COMPUTER SIMULATION; CYTIDINE DEAMINASE; GENE EXPRESSION; GENETIC THERAPY; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; VIRUS REPLICATION;

EID: 84878070888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063984     Document Type: Article

References (95)

1. Albin JS, Harris RS, (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
2. Sheehy AM, Erthal J, (2012) APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Molecular Biology International 2012: 11.
3. Wissing S, Galloway NLK, Greene WC, (2010) HIV-1 Vif versus the APOBEC3 cytidine deaminases: An intracellular duel between pathogen and host restriction factors. Molecular Aspects of Medicine 31: 383-397.
4. Strebel K, Luban J, Jeang K-T, (2009) Human cellular restriction factors that target HIV-1 replication. BMC Medicine 7: 48.
5. Chiu YL, Greene WC, (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353.
6. Malim MH, (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-687.
7. Malim MH, Bieniasz PD (2012) HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harbor Perspectives in Medicine.
8. Koito A, Ikeda T, (2012) Apolipoprotein B mRNA-editing, catalytic polypeptide cytidine deaminases and retroviral restriction. Wiley Interdisciplinary Reviews: RNA 3: 529-541.
9. Smith HC, (2011) APOBEC3G: a double agent in defense. Trends in Biochemical Sciences 36: 239-244.
10. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
11. Suspène R, Sommer P, Henry M, Ferris S, Guétard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucl Acids Res 32: 2421-2429.
12. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA Deamination Mediates Innate Immunity to Retroviral Infection. Cell 113: 803-809.
13. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
14. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
15. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the Absence of the Vif Protein. Science 300: 1112-.
16. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. J Virol: JVI.00272-00207.
17. Li X-Y, Guo F, Zhang L, Kleiman L, Cen S, (2007) APOBEC3G Inhibits DNA Strand Transfer during HIV-1 Reverse Transcription. Journal of Biological Chemistry 282: 32065-32074.
18. Bishop KN, Verma M, Kim E-Y, Wolinsky SM, Malim MH, (2008) APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts. PLoS Pathog 4: e1000231.
19. Iwatani Y, Chan DSB, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Research 35: 7096-7108.
20. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L, (2006) Inhibition of tRNA3Lys-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication. J Virol 80: 11710-11722.
21. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, et al. (2007) The interaction of APOBEC3G with Human Immunodeficiency Virus Type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol: JVI.00162-00107.
22. Luo K, Wang T, Liu B, Tian C, Xiao Z, et al. (2007) Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation. J Virol 81: 7238-7248.
23. Bishop KN, Holmes RK, Malim MH, (2006) Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination. J Virol 80: 8450-8458.
24. Newman ENC, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity. Current Biology 15: 166-170.
25. Yang Y, Guo F, Cen S, Kleiman L, (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365: 92-100.
26. Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, et al. (2007) T Cells Contain an RNase-Insensitive Inhibitor of APOBEC3G Deaminase Activity. PLoS Pathog 3: e135.
27. von Schwedler U, Song J, Aiken C, Trono D, (1993) vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67: 4945-4955.
28. Sova P, Volsky DJ, (1993) Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol 67: 6322-6326.
29. Simon JHM, Malim MH, (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 70: 5297-5305.
30. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, et al. (2003) The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity. J Virol 77: 11398-11407.
31. Schröfelbauer B, Chen D, Landau NR, (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceedings of the National Academy of Sciences of the United States of America 101: 3927-3932.
32. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR, (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the United States of America 101: 3770-3774.
33. Huthoff H, Malim MH, (2007) Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation. J Virol 81: 3807-3815.
34. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
35. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, et al. (2004) Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway. Journal of Biological Chemistry 279: 7792-7798.
36. Marin M, Rose KM, Kozak SL, Kabat D, (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
37. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability. Molecular cell 12: 591-601.
38. Conticello SG, Harris RS, Neuberger MS, (2003) The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G. Current biology: CB 13: 2009-2013.
39. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T, (2005) Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C Complex Is Essential for Vif Function. Journal of Biological Chemistry 280: 18573-18578.
40. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex. Science 302: 1056-1060.
41. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, et al. (2003) Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. Cell 114: 21-31.
42. Hosseini I, Mac Gabhann F, (2012) Multi-Scale Modeling of HIV Infection in vitro and APOBEC3G-Based Anti-Retroviral Therapy. PLoS Comput Biol 8: e1002371.
43. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK, (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83: 1992-2003.
44. Mangeat B, Turelli P, Liao S, Trono D, (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279: 14481-14483.
45. Sadler HA, Stenglein MD, Harris RS, Mansky LM, (2010) APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis. Journal of Virology 84: 7396-7404.
46. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, et al. (2007) Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1. Journal of Virology 81: 13346-13353.
47. Jin X, Brooks A, Chen H, Bennett R, Reichman R, et al. (2005) APOBEC3G/CEM15 (hA3G) mRNA Levels Associate Inversely with Human Immunodeficiency Virus Viremia. Journal of Virology 79: 11513-11516.
48. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation. Journal of Virology 80: 9259-9269.
49. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya. Journal of Virology 82: 8172-8182.
50. Ulenga NK, Sarr AD, Hamel D, Sankale J-L, Mboup S, et al. (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 1285-1290.
51. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankalé J-L, Eisen G, et al. (2008) Relationship between Human Immunodeficiency Type 1 Infection and Expression of Human APOBEC3G and APOBEC3F. Journal of Infectious Diseases 198: 486-492.
52. Vázquez-Pérez JA, Ormsby CE, Hernández-Juan R, Torres KJ, Reyes-Terán G, (2009) APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6: 23.
53. Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT, (2012) APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology 430: 1-9.
54. Cho S-J, Drechsler H, Burke RC, Arens MQ, Powderly W, et al. (2006) APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4+ T-Cell Count. Journal of Virology 80: 2069-2072.
55. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82: 3125-3130.
56. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J, (2009) Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif. Journal of Virology 83: 7805-7814.
57. Amoêdo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, et al. (2011) Expression of APOBEC3G/3F and G-to-A Hypermutation Levels in HIV-1-Infected Children with Different Profiles of Disease Progression. PLoS ONE 6: e24118.
58. Mous K, Jennes W, Camara M, Seydi M, Daneau G, et al. (2012) Expression Analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and Tetherin in a Senegalese Cohort of HIV-1-Exposed Seronegative Individuals. PLoS ONE 7: e33934.
59. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, et al. (2007) Apolipoprotein B mRNA-Editing Enzyme, Catalytic Polypeptide-Like 3G: A Possible Role in the Resistance to HIV of HIV-Exposed Seronegative Individuals. Journal of Infectious Diseases 195: 960-964.
60. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614 doi: 610.1038/nri3262.
61. Durand CM, Blankson JN, Siliciano RF (2012) Developing strategies for HIV-1 eradication. Trends in Immunology.
62. Dieffenbach CW, Fauci AS, (2011) Thirty Years of HIV and AIDS: Future Challenges and Opportunities. Annals of Internal Medicine 154: 766-771.
63. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
64. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-Based Gene Therapy for HIV with Lentiviral Vector-Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma. Science Translational Medicine 2: 36ra43.
65. Holt N, Wang J, Kim K, Friedman G, Wang X, et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotech 28: 839-847.
66. Rossi JJ, June CH, Kohn DB, (2007) Genetic therapies against HIV. Nat Biotech 25: 1444-1454.
67. Henrich TJ, Sciaranghella G, Li JZ, Gallien S, Ho V, et al. (2012) Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation in two HIV-positive individuals. 19th International AIDS Conference.
68. Kitchen S, Levin B, Bristol G, Rezek V, Kim S, et al. (2012) In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. 19th International AIDS Conference.
69. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al. (2009) Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. New England Journal of Medicine 360: 692-698.
70. Hütter G, Ganepola S, (2011) Eradication of HIV by Transplantation of CCR5-Deficient Hematopoietic Stem Cells. The Scientific World Journal 11: 1068-1076.
71. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117: 2791-2799.
72. Voit RA, McMahon MA, Sawyer SL, Porteus MH (2013) Generation of an HIV Resistant T-cell Line by Targeted [ldquo]Stacking[rdquo] of Restriction Factors. Mol Ther.
73. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
74. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
75. Bonhoeffer S, May RM, Shaw GM, Nowak MA, (1997) Virus dynamics and drug therapy. Proceedings of the National Academy of Sciences 94: 6971-6976.
76. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
77. Perelson AS, (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2: 28-36.
78. Wodarz D, Nowak MA, (2002) Mathematical models of HIV pathogenesis and treatment. BioEssays 24: 1178-1187.
79. Perelson AS, Kirschner DE, De Boer R, (1993) Dynamics of HIV infection of CD4+ T cells. Mathematical Biosciences 114: 81-125.
80. De Boer RJ, Perelson AS, (1998) Target Cell Limited and Immune Control Models of HIV Infection: A Comparison. Journal of Theoretical Biology 190: 201-214.
81. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. The Lancet 354: 1782-1785.
82. Nelson PW, Perelson AS, (2002) Mathematical analysis of delay differential equation models of HIV-1 infection. Mathematical Biosciences 179: 73-94.
83. Dixit NM, Perelson AS, (2005) HIV dynamics with multiple infections of target cells. Proceedings of the National Academy of Sciences of the United States of America 102: 8198-8203.
84. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF, (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proceedings of the National Academy of Sciences 105: 4832-4837.
85. Sedaghat AR, Siliciano RF, Wilke CO, (2008) Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8: 2.
86. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling Plasma Virus Concentration during Primary HIV Infection. Journal of Theoretical Biology 203: 285-301.
87. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV, (1999) Viral Dynamics of Acute HIV-1 Infection. The Journal of Experimental Medicine 190: 841-850.
88. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, et al. (2010) Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. Journal of Virology 84: 6096-6102.
89. Refsland EW, Hultquist JF, Harris RS, (2012) Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n. PLoS Pathog 8: e1002800.
90. Felber B, Pavlakis G, (1988) A quantitative bioassay for HIV-1 based on trans-activation. Science 239: 184-187.
91. Kimpton J, Emerman M, (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 66: 2232-2239.
92. Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW, (1994) A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res Hum Retroviruses 10: 295-301.
93. UNAIDS (2010) UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS.
94. Jeffrey Fessel W, (2005) A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem. Medical Hypotheses 64: 261-263.
95. Miller JH, Presnyak V, Smith HC, (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4: 81.